Hepatic artery-infusion chemotherapy improved survival of hepatocellular carcinoma after radical hepatectomy

Min Feng¹
Chengwu Tang¹
Wenming Feng¹
Ying Bao¹
Yinyuan Zheng²
Jianbin Shen¹

¹Department of General Surgery, ²Department of Radiology, First People’s Hospital, Huzhou University Medical College, Huzhou, Zhejiang, China

Objective: To evaluate the effect of postoperative hepatic artery-infusion chemotherapy (HAIC) on survival probability in patients with hepatocellular carcinoma (HCC) after radical hepatectomy.

Patients and methods: This retrospective study included 85 patients with HCC who received radical hepatectomy from May 2005 to May 2010. Among these patients, 42 underwent two sessions of HAIC (5-fluorouracil [1,000 mg/m²], oxaliplatin [85 mg/m²], and mitomycin-C [6 mg/m²]) after radical hepatectomy (HAIC group), and 43 underwent radical hepatectomy only (the control group). HAIC-related side effects and long-term survival were retrospectively analyzed.

Results: The HAIC group showed a significantly higher 5-year intrahepatic recurrence-free survival probability and lower risk of intrahepatic recurrence (HR 0.5615, 95% CI 0.3234–0.9749 [log-rank test]; P=0.0332). The HAIC group also had significantly higher 5-year disease-free survival probability (HR 0.591, 95% CI 0.3613–0.9666 [log-rank test]; P=0.0298) and overall survival probability than the control group (HR 0.5768, 95% CI 0.3469–0.9589 [log-rank test]; P=0.0278). No HAIC-related deaths in the HAIC group were reported. All toxicities and complications were controlled, and no patients quit the treatment.

Conclusion: HAIC can effectively and safely reduce intrahepatic recurrence and improve the long-term survival of patients with HCC after radical hepatectomy.

Keywords: hepatocellular carcinoma, hepatic artery-infusion chemotherapy, intrahepatic recurrence, metastasis

Introduction

Hepatocellular carcinoma (HCC) leads to 690,000 deaths annually worldwide. More than half of these deaths occur in China, and thus the disease is considered the second-most fatal cancer in the country.¹ Various treatment options are currently available, such as surgical resection, radiofrequency ablation, percutaneous ethanol injection, transcatheter arterial chemoembolization, radiotherapy, and hepatic artery-infusion chemotherapy (HAIC).²

Radical resection is the optimal therapy for patients with HCC with early disease stage and good liver-function reserve.³,⁴ However, more than 80% of patients with HCC develop recurrence within 5 years after radical hepatectomy, which significantly harms long-term survival.⁵–⁷ Postoperative recurrence of HCC is related to multicenter growth of tumor and microscopic tumor thrombosis.⁸–⁹ Both univariate and multivariate analyses of the prognostic factors indicate that intrahepatic recurrence significantly affects survival.¹⁰,¹¹ Macroscopic tumor foci are resected by surgery; however,
undetected residual microscopic foci will then lead to relapse. Therefore, elimination of the residual microscopic foci plays an important role in improving the long-term survival of HCC after surgery. The present study aims to determine the safety and efficacy of HAIC in patients with HCC after radical hepatectomy.

**Patients and methods**

**Patients**

The medical records of 85 patients with HCC who had received radical hepatectomy in our hospital from May 2005 to May 2010 were retrospectively analyzed. Baseline characteristics – age, sex, serum AFP level, operating time, blood loss during surgery, etiology, degree of cirrhosis, resection modalities, microvascular invasion (MVI), Child–Pugh stage, tumor size, number of tumors, and tumor differentiation – were collected and compared. The presence of MVI was determined by pathological findings from surgical specimens.

Among the patients, 42 underwent two courses of HAIC after radical hepatectomy (HAIC group) and 43 underwent radical hepatectomy without postoperative HAIC (control group). Entry criteria were 1) age 18–75 years, 2) Karnofsky performance score ≥70, 3) no allergy to the chemotherapy agent, 4) no previous anticancer therapy, 5) Child–Pugh class A–B, 6) no portal vein thrombosis or systemic metastasis, 7) no refractory ascites or organ dysfunction, 8) no recurrence or remnant tumor detected within 1 month after radical hepatectomy, and 9) full follow-up data.

The protocol was approved by the ethics committee of the First People’s Hospital, affiliated to Huzhou Normal College, and followed the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Signed informed consent was obtained from all patients.

**HAIC administration**

HAIC was administered within 3 weeks after surgery for two sessions, with an interval of 4 weeks. The procedure included oxaliplatin (Oxa; 85 mg/m²) as a 2-hour infusion, followed by fluorouracil (5FU; 1,000 mg/m²) as a 5-hour infusion and mitomycin C (6 mg/m²) as a >1-hour infusion. HAIC was administered via a catheter, with one tip inserted into the common hepatic artery or proper hepatic artery and the other end connected to the micropump. The catheter was removed after HAIC. Patients were carefully monitored, and symptomatic treatments were administered. Treatment would be terminated in cases of life-threatening side effects or upon the request of the patient.

**Assessment and follow-up**

All complications and toxicities assessed according to the Common Terminology Criteria for Adverse Events (version 4.0) were recorded. Patients were followed up every 4 weeks in the first year after surgery and every 3 months thereafter. The follow-up assessment included physical examination, biological testing, AFP level, chest radiography, abdominal ultrasonography and computed tomography, or magnetic resonance imaging. Recurrence was diagnosed by imaging and if necessary biopsy. Once recurrence or metastasis was confirmed, transcatheter arterial chemoembolization, radiofrequency ablation, or surgery was performed.

**Statistical analysis**

Data are expressed as means ± SD. Statistical analysis was conducted using the two-sample t-test and adjusted \( P = 0.05 \) was considered statistically significant.

**Results**

**Baseline characteristics**

Baseline characteristics are listed in Table 1. No significant differences in age, sex, serum AFP level, operating time, blood loss during surgery, etiology, degree of cirrhosis, resection modalities, MVI, Child–Pugh stage, tumor size, number of tumors, or tumor differentiation were indicated.

**Intrahepatic recurrence-free survival**

In the first 5 postoperative years, 23 of 42 patients in the HAIC group and 29 of 43 patients in the control group developed intrahepatic recurrence. The HAIC group obtained significantly higher intrahepatic recurrence-free survival probability (HR 0.5615, 95% CI 0.3234–0.9749 [log-rank test]; \( P=0.0332 \)) (Figure 1).

**Disease-free survival**

In the first 5 postoperative years, 29 patients in the HAIC group and 36 patients in the control group developed recurrence. The 5-year disease-free survival probability was significantly higher in the HAIC group than in the control group (HR 0.591, 95% CI 0.3613–0.9666 [log-rank test]; \( P=0.0298 \)) (Figure 2).
Overall survival
In the first 5 postoperative years, 27 patients in the HAIC group and 34 patients in the control group had died. The HAIC group obtained significantly higher overall survival probability than the control group (HR 0.5768, 95% CI 0.3469–0.9589; P=0.0278) (Figure 3).

Toxicity and complications
No HAIC-induced deaths in the HAIC group were reported. Patients in the HAIC group mainly experienced paresthesia (14 of 42), neutropenia (15 of 42), thrombocytopenia (16 of 42), anemia (10 of 42), nausea or vomiting (30 of 42),...
diabetes (8 of 42), and hepatic toxicity (25 of 42). All toxicities and complications were controlled, and no patients quit the treatment.

Discussion

HCC is a global public health problem, and causes millions of death annually worldwide. It is considered one of the most common cancers in China.13 Due to the difficulty of early diagnosis and the high frequency of metastasis and recurrence, the prognosis of HCC remains poor.

Liver tumors have been demonstrated to receive abundant blood supply from the hepatic artery.14–16 HAIC is a hepatically directed treatment that takes advantage of relatively selective hepatic arterial tumor vascularization. Several meta-analyses and clinical studies have concluded that postoperative HAIC can decrease recurrence after surgery and improve long-term survival.17–19 HAIC draws interest as a potential treatment option, because compared with intravenous infusion, extraction of chemotherapeutic drugs from the hepatic arterial circulation via the first-pass effect can produce higher local concentrations and fewer systemic side effects. Accordingly, we started the protocol of arterial infusion of Oxa (85 mg/m² on day 1) followed by SFU (1,000 mg/m² on day 1) and mitomycin C (6 mg/m²). The feasibility and safety of HAIC with Oxa, mitomycin C, and SFU for HCC treatment have been reported previously.20

In the current study, fewer patients in the HAIC group than in the control group developed intrahepatic recurrence during the first 5 years after surgery. The HAIC group obtained significantly higher 5-year intrahepatic recurrence-free survival probability and lower risk of intrahepatic recurrence (HR 0.5615, 95% CI 0.3234–0.9749; P=0.0332). Consequently, the HAIC group also obtained significantly higher 5-year disease-free survival (HR 0.591, 95% CI 0.3613–0.9666; P=0.0298) and overall survival probability compared with the control group (HR 0.5768, 95% CI 0.3469–0.9589 [log-rank test]; P=0.0278). No HAIC-related deaths in the HAIC group were reported. No patients quit the treatment because of uncontrollable toxicities or complications.

In conclusion, HAIC is an effective and safe procedure for preventing postoperative intrahepatic recurrence and improving the long-term survival of patients with HCC after curative resection. The current protocol can be safely employed in a prospective randomized study.

Acknowledgment

This study was supported by the Foundation of Huzhou Bureau of Science and Technology (grant 2016YZB02).

Author contributions

MF, CWT, and JBS designed the study and wrote the manuscript. MF and CWT contributed equally to this study. WMF, YB, and YYZ conducted patient management and monitoring. YB and WMF collected and analyzed the data. All authors contributed toward data analysis, drafting, and revising the paper, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References